Search results for "Streptococcus pneumoniae"

showing 10 items of 38 documents

Mitochondrial dysfunction and host immune response during pneumococcal pneumonia : impact of mechanical ventilation?

2020

Lung damage induced by mechanical ventilation (MV) worsens the prognosis of pneumonia. Mitochondrial dysfunctions could account for such deleterious effects. Accordingly, data obtained from both in vitro and in vivo experimental studies, as well as in ventilated patients with acute respiratory distress syndrome, show that mitochondrial alarmins, especially mitochondrial DNA, are released in the alveolar compartment as a result of the cyclic stretch, and could thus represent one link between the mechanical insult and the sterile inflammation leading to VILI (ventilator-induced lung injury). In rabbits, we show herein that adverse and prolonged MV worsens the prognosis of pneumococcal pneumon…

Pneumopathie[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyStreptococcus pneumoniaeMechanical ventilationBiogénèse mitochondrialeMitochondrial biogenesisVentilation mécaniqueMitophagyDysfonction mitochondrialePneumoniaMitochondrial dysfunctionMitophagie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemothera…

2003

Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the…

Potential impactChemotherapymedicine.medical_specialtyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industrymedicine.medical_treatmentPublic Health Environmental and Occupational HealthAntimicrobialmedicine.disease_causeClinical trialInfectious DiseasesPneumococcal vaccineImmunizationStreptococcus pneumoniaeImmunologyMolecular MedicineMedicinebusinessIntensive care medicineConjugateVaccine
researchProduct

Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.

1991

A year long multicentre prospective study was carried out in the Valencia region of Spain, to determine the cause of community acquired pneumonia. The study was based on 510 of 833 patients with pneumonia. Of these, 462 were admitted to hospital, where 31 patients died. A cause was established in only 281 cases--208 of bacterial, 60 of viral, and 13 of mixed infection. The most common microorganisms were Streptococcus pneumoniae (14.5%), Legionella sp (14%), Influenza virus (8%), and Mycoplasma pneumoniae (4%). There was a higher incidence of Legionella sp than in other studies.

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyMycoplasma pneumoniaeAdolescentPneumonia Viralmedicine.disease_causeCommunity-acquired pneumoniaInternal medicineStreptococcus pneumoniaeInfluenza A virusmedicineHumansProspective StudiesProspective cohort studyAgedbusiness.industryIncidence (epidemiology)PneumoniaMiddle Agedmedicine.diseaseMycoplasma pneumoniaerespiratory tract diseasesHospitalizationPneumoniaStreptococcus pneumoniaeInfluenza A virusSpainImmunologyEtiologyFemalebusinessResearch Article
researchProduct

Factors associated with influenza vaccination of hospitalized elderly patients in Spain

2016

Vaccination of the elderly is an important factor in limiting the impact of influenza in the com- munity. The aim of this study was to investigate the factors associated with influenza vacci- nation coverage in hospitalized patients aged 65 years hospitalized due to causes unrelated to influenza in Spain. We carried out a cross-sectional study. Bivariate analysis was performed comparing vaccinated and unvaccinated patients, taking in to account sociodemographic variables and medical risk conditions. Multivariate analysis was per- formed using multilevel regression models. We included 1038 patients: 602 (58%) had received the influenza vaccine in the 2013 - 14 season. Three or more general p…

RNA virusesMaleViral Diseaseslcsh:MedicineGlobal HealthPersones gransGeographical LocationsPneumococcal VaccinesElderlyMedicine and Health SciencesPublic and Occupational HealthVacunaciólcsh:SciencePathology and laboratory medicineAged 80 and overVaccinesVaccinationMedical microbiologyVaccination and ImmunizationEuropeInfectious DiseasesStreptococcus pneumoniaeInfluenza A virusInfluenza VaccinesVirusesFemalePathogensAssistència hospitalàriaResearch ArticleImmunologyMicrobiologyInfluenzavirusPatient Education as TopicInfluenza HumanHumansInfluenza virusesEspanyaAgedInpatientsHospital careMarital Statuslcsh:ROrganismsViral pathogensBiology and Life SciencesPneumonia PneumococcalInfluenzaMicrobial pathogensCross-Sectional StudiesSocial ClassAge GroupsSpainPeople and PlacesPopulation Groupingslcsh:QPreventive MedicineOlder peopleOrthomyxoviruses
researchProduct

Sepsis due to Streptococcus pneumoniae associated with secondary hemophagocytic lymphohistiocytosis in a splenectomized patient for spherocytosis

2017

Abstract Rationale: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome that is characterized by an inappropriate hyperinflammatory immune response – primary, as a consequence of a genetic defect of NK cells and cytotoxic T lymphocytes or – secondary, in the progression of infections, rheumatic or autoimmune diseases, malignancies or metabolic diseases. Patient concerns: We present the case of a secondary HLH due to Streptococcus pneumoniae infection in a splenectomised patient for spherocytosis, a 37-year-old patient who was splenectomised in childhood for spherocytosis, without immuneprophylaxis induced by antipneumococcal vaccine. Outcomes: He developed a severe pneumococcal sepsis as…

Secondary Hemophagocytic LymphohistiocytosisAdultMaleendocrine systemsplenectomized patientmedicine.medical_treatmentSpherocytosisSplenectomySpherocytosis Hereditarymedicine.disease_causeLymphohistiocytosis HemophagocyticPneumococcal InfectionsSepsis03 medical and health sciences0302 clinical medicineImmune systemFatal Outcomehemic and lymphatic diseasesSepsisStreptococcus pneumoniaemedicineCytotoxic T cellHumans030212 general & internal medicineClinical Case ReportHemophagocytic lymphohistiocytosisbusiness.industry4900General Medicinemedicine.diseaseStreptococcus pneumoniaehemophagocytic lymphohistiocytosis030220 oncology & carcinogenesisImmunologySplenectomybusinessResearch ArticleHLHMedicine
researchProduct

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipien…

2009

The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly …

SerotypeAdultMaleHeptavalent Pneumococcal Conjugate VaccineAdolescentActive immunizationcomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesYoung Adultstomatognathic systemConjugate vaccineHeptavalent Pneumococcal Conjugate VaccinemedicineHumansTransplantation HomologousSeroconversionChildTransplantationGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPneumococcal vaccineMiddle AgedAntibodies BacterialAllogeneic stem cell transplantationVaccinationInfectious DiseasesStreptococcus pneumoniaePneumococcal vaccineImmunologyMolecular MedicineFemalebusinessPneumococcal infectionmedicine.drugStem Cell Transplantation
researchProduct

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vacc…

2010

13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing pneumococcal disease caused by the common serotypes and m…

SerotypeMaleHeptavalent Pneumococcal Conjugate Vaccinemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal Vaccinesstomatognathic systemDouble-Blind MethodGermanyStreptococcus pneumoniaemedicineHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ScheduleVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPneumococcal infectionsInfectious DiseasesImmunizationImmunoglobulin GImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Single tube real time PCR for detection of Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila from …

2012

We designed a multiplex real time PCR for rapid, sensitive and specific detection of Streptococcus pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae and Mycoplasma pneumoniae. The study cases consisted of 129 patients with community acquired pneumonia (CAP). Bacteriological techniques were implemented for detection of the cultivable organisms. DNA were extracted from sputa, throat swabs, bronchoalveolar lavages and tracheal aspirates and used as templates in real time PCR. The primers and probes were designed for cbpA (S. pneumoniae), p1adhesin (M. pneumoniae), mip (L. pneumophila) and ompA (C. pneumoniae). After optimization of real time PCR for every organism, the experiments w…

Settore MED/07 - Microbiologia E Microbiologia ClinicaMycoplasma pneumoniaemedicine.disease_causeReal-Time Polymerase Chain ReactionLegionella pneumophilaSensitivity and SpecificityMicrobiologyLegionella pneumophilaCommunity-acquired pneumoniacommunity acquired pneumonia CAP real time PCR Streptococcus pneumonia Legionella pneumophila Chlamydophila pneumonia Mycoplasma pneumoniaeStreptococcus pneumoniaeMultiplex polymerase chain reactionmedicinePneumonia BacterialHumansMultiplexGeneral Immunology and MicrobiologybiologyBacteriaGeneral MedicineChlamydophila pneumoniaebiology.organism_classificationmedicine.diseaseVirologyrespiratory tract diseasesMycoplasma pneumoniaeCommunity-Acquired InfectionsReal-time polymerase chain reactionStreptococcus pneumoniaeChlamydophila pneumoniaeMultiplex Polymerase Chain ReactionActa microbiologica et immunologica Hungarica
researchProduct

No klīniskajiem paraugiem izdalīto Streptococcus pneumoniae virulences faktori un rezistence pret antibakteriālajiem līdzekļiem

2020

Ievads: Latvijā un Pasaulē aktuāla problēma ir Streptococcus pneumoniae baktērijas rezistence, kas izveidojusies pret antibakteriālajiem līdzekļiem. Rezistento Streptococcus pneumoniae celmu skaits palielinās ar katru gadu. Preventīvie pasākumi, kas samazinātu rezistences incidenci ir svarīga atbildīga un piesardzīga antibakteriālo līdzekļu izmantošana cilvēku veselības uzlabošanai un pacientu informētība, izpratne par Streptococcus pneumoniae rezistenci. Darba mērķi: Noteikt Streptecoccus pneumoniae jutību pret antibakteriālajiem līdzekļiem, kas iegūti no klīniskā materiāla paraugiem. Materiāli un metodes: Pētījums veikts RAKUS stacionārs ‘’Tuberkulozes un plaušu slimību centrs’’ klīnikas …

Streptococcus pneumoniaeantibakteriālā rezistenceantibakteriālie līdzekļigram pozitīvās baktērijasvirulences faktoriMedicīna
researchProduct

No klīniskā materiāla izdalīto Streptococcus pneumoniae jutība pret antibakteriālajiem līdzekļiem

2016

Nozīmīga sabiedrības veselības problēma ir baktēriju rezistence pret antibakteriālajiem līdzekļiem. Pasaulē parādās arvien jauni pret antibakteriālajiem līdzekļiem rezistenti S. pneumoniae celmi. Tas galvenokārt, saistīts ar antibakteriālo līdzekļu nepareizu pielietošanu un plaša spektra preparātu lietošanu, kad ir iespējams izmantot šaura spektra antibakteriālus līdzekļus. Darba mērķis: Noteikt S. pneumoniae jutību pret antibakteriālajiem līdzekļiem, celmiem, kas izdalīti no klīniskā materiāla. Darba uzdevumi: Veikt laboratorijā identificēto S. pneumoniae jutības testus pret antibakteriālajiem līdzekļiem, pielietojot BBLTM DDT un BBLTM E – testu, analizēt statistiskos datus, izmantojot Mic…

Streptococcus pneumoniaeantibakteriālā rezistencesuscepibility testsjutības testiantibacterial resistanceFarmācija
researchProduct